1.1.1.211	degradation	when gene encoding 3-hydroxyacyl-CoA dehydrogenase is deleted, it is possible to produce medium-chain-length polyhydroxyalkanoates containing only two different monomer structures	
1.1.1.211	diagnostics	3-hydroxypalmitoleoyl-carnitine and other hydroxylated long chain acylcarnitines are markers of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) and/or trifunctional protein (TFP) deficiency, while heptadecanoylcarnitine is a biomarker specific for propionic acidemia (PA) or methylmalonic acidemia (MMA) patients able to detect propionate disorders during expanded newborn screening	
1.1.1.211	medicine	inverse correlation between enzyme activity and gestational age during second and third trimester of pregnancy, involvement of enzyme defects in a subset of pregnancy complications	
1.1.1.211	medicine	treatment of patients with defects in enzymic activity, provision of odd-chain species of medium fatty acids decreases the build-up of long-chain fatty acid oxidation intermediates in an in vitro skin fibroblast model	
1.1.1.211	medicine	case study on a Korean male newborn who presented with severe lactic acidosis, seizures, and heart failure and an increase of 3-hydroxy species: 3-OH-palmitoylcarnitine, at 0.44 nmol/ml, 3-hydroxylinoleylcarnitine, at 0.31 nmol/ml, and 3-hydroxyoleylcarnitine, at 0.51 nmol/ml. The findings suggest either long-chain 3-hydroxyacyl-coA dehydrogenase deficiency or complete MTP deficiency. The patient was a compound heterozygote for c.358dupT and c.1364T>G mutations. Although the patient was treated by reduction of glucose administration and supplementation of a medium-chain triglyceride-based diet with L-carnitine, he died 2 months after birth due to advanced cardiac failure